11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 3051-3060

  Tiganescu, Ana ^a   Tahrani, Abd A ^a   Morgan, Stuart A ^a   Otranto, Marcela ^b,c   Desmoulière, Alexis ^b   Abrahams, Lianne ^a   Hassan Smith, Zaki ^a   Walker, Elizabeth A ^a   Rabbitt, Elizabeth H ^a   Cooper, Mark S ^a   Amrein, Kurt ^d   Lavery, Gareth G ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LIMOGES   (France)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; COLLAGEN; GLUCOCORTICOID; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CUTANEOUS PARAMETERS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN FIBROBLAST; SKIN FUNCTION; SKIN STRUCTURE; VOLUNTEER; WOUND HEALING; WOUND HEALING IMPAIRMENT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADULT; AGED; AGED, 80 AND OVER; AGING; ANIMALS; CELLS, CULTURED; COLLAGEN; FEMALE; FIBROBLASTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PRIMARY CELL CULTURE; SKIN; WOUND HEALING; YOUNG ADULT;

EID: 84879638689     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64162     Document Type: Article

References (59)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006; 367(9522):1605-1617. (Pubitemid 43674231)
2. Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol. 2002;15(2):85-91. (Pubitemid 34195792)
3. Werth VP, Kligman AM, Shi XM, Pagnoni A. Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid. Arch Dermatol Res. 1998;290(7):388-393. (Pubitemid 28408563)
4. Sowers JR, Lippman HR. Cushing's syndrome due to ectopic ACTH production: cutaneous manifestations. Cutis. 1985;36(4):351-352.
5. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology. 1992;130(6):3378-3386.
6. Faergemann J, et al. Dose-response effects of tri-iodothyroacetic acid (Triac) and other thyroid hormone analogues on glucocorticoid-induced skin atrophy in the haired mouse. Acta Derm Venereol. 2002;82(3):179-183. (Pubitemid 34848391)
7. Kimura T, Doi K. Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids. Toxicol Pathol. 1999;27(5):528-535. (Pubitemid 29446821)
8. Nuutinen P, et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol. 2003;148(1):39-45. (Pubitemid 36114859)
9. Autio P, Oikarinen A, Melkko J, Risteli J, Risteli L. Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br J Dermatol. 1994;131(5):660-663. (Pubitemid 24344051)
10. Oishi Y, Fu ZW, Ohnuki Y, Kato H, Noguchi T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol. 2002;147(5):859-868. (Pubitemid 35365431)
11. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406-420.
12. Lee B, Vouthounis C, Stojadinovic O, Brem H, Im M, Tomic-Canic M. From an enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF leads to inhibition of wound healing. J Mol Biol. 2005;345(5):1083-1097. (Pubitemid 40092226)
13. Mercado AM, Padgett DA, Sheridan JF, Marucha PT. Altered kinetics of IL-1 alpha, IL-1 beta, and KGF-1 gene expression in early wounds of restrained mice. Brain Behav Immun. 2002;16(2):150-162. (Pubitemid 35425571)
14. Aberg KM, et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest. 2007;117(11):3339-3349. (Pubitemid 350096990)
15. Lavker RM. Structural alterations in exposed and unexposed aged skin. J Invest Dermatol. 1979;73(1):59-66. (Pubitemid 10136110)
16. Varani J, et al. Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol. 2000;114(3):480-486. (Pubitemid 30415333)
17. Braverman IM, Fonferko E. Studies in cutaneous aging: I. The elastic fiber network. J Invest Dermatol. 1982;78:434-443. (Pubitemid 12100911)
18. Varani J, et al. Decreased collagen production in chronologically aged skin - roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am J Pathol. 2006;168(6):1861-1868. (Pubitemid 43825306)
19. Liang JA, Pei XR, Zhang ZF, Wang N, Wang JB, Li Y. The protective effects of long-term oral administration of marine collagen hydrolysate from chum salmon on collagen matrix homeostasis in the chronological aged skin of Sprague-Dawley male rats. J Food Sci. 2010;75(8):H230-H238.
20. Sayama A, Soushin T, Okada T, Doi K, Nakayama H. Morphological and biochemical changes during aging and photoaging of the skin of C57BL/6J mice. J Toxicol Pathol. 2010;23(3):133-139.
21. Ghadially R, Brown BE, Sequeiramartin SM, Feingold KR, Elias PM. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J Clin Invest. 1995;95(5):2281-2290.
22. Escoffier C, Derigal J, Rochefort A, Vasselet R, Leveque JL, Agache PG. Age-related mechanical-properties of human-skin - an in vivo study. J Invest Dermatol. 1989;93(3):353-357. (Pubitemid 19216071)
23. Ashcroft GS, Horan MA, Ferguson MWJ. Aging is associated with reduced deposition of specific extracellular matrix components, upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. J Invest Dermatol. 1997;108(4):430-437. (Pubitemid 27148277)
24. Ballas CB, Davidson JM. Delayed wound healing in aged rats is associated with increased collagen gel remodeling and contraction by skin fibroblasts, not with differences in apoptotic or myofibroblast cell populations. Wound Repair Regen. 2001;9(3):223-237. (Pubitemid 32706270)
25. Beauregard S, Gilchrest BA. A survey of skin problems and skin care regimens in the elderly. Arch Dermatol. 1987;123(12):1638-1643. (Pubitemid 18012177)
26. Tiganescu A, Walker EA, Hardy RS, Mayes AE, Stewart PM. Localization, age- and site-dependent expression, and regulation of 11β-hydroxysteroid dehydrogenase type 1 in skin. J Invest Dermatol. 2011;131(1):30-36.
27. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM. Osteoblastic 11 beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res. 2002;17(6):979-986. (Pubitemid 34535135)
28. Zhang TY, Ding XH, Daynes RA. The expression of 11 beta-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J Immunol. 2005;174(2):879-889. (Pubitemid 40094283)
29. Weinstein RS, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010;9(2):147-161.
30. Holmes MC, et al. 11beta-hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J Neurosci. 2010;30(20):6916-6920.
31. Andersson T, et al. Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women. PloS One. 2009;4(12):e8475.
32. Yau JLW, et al. Enhanced hippocampal long-term potentiation and spatial learning in aged 11 beta-hydroxysteroid dehydrogenase type 1 knockout mice. J Neurosci. 2007;27(39):10487-10496. (Pubitemid 47502008)
33. Sooy K, et al. Partial deficiency or short-term inhibition of 11beta-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice. J Neurosci. 2010;30(41):13867-13872.
34. Mohler EG, et al. Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognition. J Neurosci. 2011;31(14):5406-5413.
35. Damodarasamy M, et al. Collagen extracts derived from young and aged mice demonstrate different structural properties and cellular effects in three-dimensional gels. J Gerontol A Biol Sci Med Sci. 2010;65(3):209-218.
36. Vedrenne N, Coulomb B, Danigo A, Bonté F, Desmoulière A. The complex dialogue between (myo)fibroblasts and the extracellular matrix during skin repair processes and aging. Pathol Biol (Paris). 2012;60(1):20-27.
37. Cretu A, Brooks PC. Impact of the non-cellular tumor microenvironment on metastasis: Potential therapeutic and imaging opportunities. J Cell Physiol. 2007;213(2):391-402. (Pubitemid 47509718)
38. Willhauck MJ, et al. Reversion of tumor phenotype in surface transplants of skin SCC cells by scaffold-induced stroma modulation. Carcinogenesis. 2007;28(3):595-610. (Pubitemid 46523355)
39. Bernstein EF, et al. Long-term sun exposure alters the collagen of the papillary dermis. Comparison of sun-protected and photoaged skin by northern analysis, immunohistochemical staining, and confocal laser scanning microscopy. J Am Acad Dermatol. 1996;34(2 pt 1):209-218. (Pubitemid 26063991)
40. Cutroneo KR, Counts DF. Anti-inflammatory steroids and collagen metabolism: glucocorticoid-mediated alterations of prolyl hydroxylase activity and collagen synthesis. Mol Pharmacol. 1975;11(5):632-639.
41. Benson SC, Luvalle PA. Inhibition of lysyl oxidase and prolyl hydroxylase activity in glucocorticoid treated rats. Biochem Biophys Res Commun. 1981;99(2):557-562. (Pubitemid 12195976)
42. Vranka JA, et al. Prolyl 3-hydroxylase 1 null mice display abnormalities in fibrillar collagen-rich tissues such as tendons, skin, and bones. J Biol Chem. 2010;285(22):17253-17262.
43. Cabral WA, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007;39(3):359-365. (Pubitemid 46328489)
44. Willaert A, et al. Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J Med Genet. 2009;46(4):233-241.
45. Yeowell HN, Walker LC. Mutations in the lysyl hydroxylase 1 gene that result in enzyme deficiency and the clinical phenotype of Ehlers-Danlos syndrome type VI. Mol Genet Metab. 2000;71(1-2):212-224.
46. van der Slot AJ, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem. 2003;278(42):40967- 40972.
47. Bank RA, et al. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: Indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. Proc Natl Acad Sci U S A. 1999;96(3):1054-1058. (Pubitemid 29072182)
48. Kuivaniemi H, Peltonen L, Kivirikko KI. Type IX Ehlers-Danlos syndrome and Menkes syndrome: the decrease in lysyl oxidase activity is associated with a corresponding deficiency in the enzyme protein. Am J Hum Genet. 1985;37(4):798-808. (Pubitemid 16249438)
49. Bauer EA, Kronberger A, Valle KJ, Jeffrey JJ, Eisen AZ. Glucocorticoid modulation of collagenase expression in human skin fibroblast cultures. Evidence for pre-translational inhibition. Biochim Biophys Acta. 1985;825(2):227-235. (Pubitemid 15029836)
50. Madlener M, Mauch C, Conca W, Brauchle M, Parks WC, Werner S. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J. 1996;320:659-664. (Pubitemid 26417794)
51. Bigg HF, et al. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type I-matrix metalloproteinase. Cancer Res. 2001;61(9):3610-3618. (Pubitemid 32694971)
52. Varani J, et al. Inhibition of type I procollagen synthesis by damaged collagen in photoaged skin and by collagenase-degraded collagen in vitro. Am J Pathol. 2001;158(3):931-942. (Pubitemid 32221785)
53. Hollis G, Huber R. 11 beta-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(1):1-6.
54. Feig PU, et al. Effects of an 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011;13(6):498-504.
55. Gibbs JP, et al. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor. J Clin Pharmacol. 2011;51(6):830-841.
56. Park JS, et al. Anti-diabetic and anti-adipogenic effects of a novel selective 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344). Biochem Pharmacol. 2011;81(8):1028-1035.
57. Liu J, et al. Adipose tissue-targeted 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocr J. 2011;58(3):199-209.
58. Semjonous NM, et al. Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostasis independent of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology. 2011;152(1):93-102.
59. Fuerst-Recktenwald S, Abt M, Arlt W. Effects of two 11β-HSD1 inhibitors on the hypothalamo-pituitary-adrenal axis of male and female Type 2 diabetic patients. Endocr Rev. 2011;32(03-Meeting-Abstracts):OR39-4.